Beth Palian

Beth joined ImmPACT Bio in March 2023 as Senior Director of Regulatory Affairs. Previously, she was Director of Regulatory Affairs at Neogene Therapeutics where she built out the regulatory team and led the submissions of Neogene’s first CTA and IND for their personalized and shared neoantigen TCR T cell therapy programs in solid tumors. Prior to Neogene, Beth held increasing positions of responsibility at Kite Pharma where she supported the initial BLA/MAAs for Yescarta in large B cell lymphoma and led the sBLA filing for Yescarta’s second approved indication in follicular lymphoma. Beth earned her Ph.D in Molecular and Cellular Biology from the University of Southern California and her bachelor’s degree from New York University.